{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:30:24Z","timestamp":1786116624688,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"India Ministry of Science & Technology Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bmc.2026.118733","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:50:54Z","timestamp":1782229854000},"page":"118733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Coumarin\u2013sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-0847","authenticated-orcid":false,"given":"Deep Rohan","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8452-0958","authenticated-orcid":false,"given":"Gourav","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4696-2262","authenticated-orcid":false,"given":"Shailendra","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8858-4863","authenticated-orcid":false,"given":"Varun","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3714-9112","authenticated-orcid":false,"given":"Subhamoy","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2797-3433","authenticated-orcid":false,"given":"Pranav Kumar","family":"Ambast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-9846","authenticated-orcid":false,"given":"Vaishnavi","family":"Kalmegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-6275","authenticated-orcid":false,"given":"Amit","family":"Shard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bmc.2026.118733_bb0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: a global assessment by world region and human development index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bmc.2026.118733_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-025-06277-9","article-title":"Global, regional, and national burden of ovarian cancer in women aged 45+from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 global burden of disease study","volume":"151","author":"Ren","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0020","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bmc.2026.118733_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120789","article-title":"Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs","volume":"305","author":"Famurewa","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bmc.2026.118733_bb0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3802\/jgo.2009.20.2.96","article-title":"Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer","volume":"20","author":"Joo","year":"2009","journal-title":"J. Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.bmc.2026.118733_bb0035","doi-asserted-by":"crossref","first-page":"14414","DOI":"10.1021\/acs.jmedchem.4c01203","article-title":"Palladium(II)-Indenyl complexes bearing N-heterocyclic Carbene (NHC) ligands as potent and selective Metallodrugs toward high-grade serous ovarian Cancer models","volume":"67","author":"Bortolamiol","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jorganchem.2024.123167","article-title":"Synthesis, characterization and anti-ovarian cancer activities of novel biphenyl-NHC-gold(I) complexes","volume":"1013","author":"Wang","year":"2024","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0045","article-title":"Ovarian cancer targeted therapy: current landscape and future challenges","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bmc.2026.118733_bb0050","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.12659\/MSM.907490","article-title":"Overexpression of pyruvate kinase type M2 (PKM2) promotes ovarian Cancer cell growth and survival via regulation of cell cycle progression related with upregulated CCND1 and downregulated CDKN1A expression","volume":"24","author":"Zheng","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"10.1016\/j.bmc.2026.118733_bb0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13238-015-0132-x","article-title":"Structural insight into mechanisms for dynamic regulation of PKM2","volume":"6","author":"Wang","year":"2015","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.bmc.2026.118733_bb0060","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.7150\/ijbs.59855","article-title":"Specific pyruvate kinase M2 inhibitor, compound 3K, induces Autophagic cell death through disruption of the glycolysis pathway in ovarian Cancer cells","volume":"17","author":"Park","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0065","article-title":"Correlation of pyruvate kinase M2 expression with Clinicopathological data in ovarian Cancer","volume":"38","author":"Kobierzycki","year":"2018","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.bmc.2026.118733_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182166","article-title":"Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer","volume":"12","author":"Chao","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13578-019-0317-8","article-title":"PKM2, function and expression and regulation","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"10.1016\/j.bmc.2026.118733_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155972","article-title":"Coumarins as versatile therapeutic phytomolecules: a systematic review","volume":"134","author":"Hussain","year":"2024","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6492346","article-title":"Natural Coumarins: exploring the pharmacological complexity and underlying molecular mechanisms","volume":"2021","author":"Sharifi-Rad","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bmc.2026.118733_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s12291-025-01372-7","article-title":"Coumarin derivatives in Cancer therapy: genetic insights and molecular mechanisms","author":"Mustafa","year":"2025","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.bmc.2026.118733_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.bmc.2026.118733_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70210","article-title":"Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer","volume":"13","author":"Hartwich","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bmc.2026.118733_bb0105","article-title":"FDA approves first-ever drug combo for low-grade serous ovarian Cancer","author":"Rddad","year":"2025","journal-title":"Oncol News Cent."},{"issue":"25","key":"10.1016\/j.bmc.2026.118733_bb0110","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2017-09-804666","article-title":"Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase","volume":"131","author":"Rishavy","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bmc.2026.118733_bb0115","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.tem.2023.08.008","article-title":"Unleashing ferroptosis for cancer therapy with warfarin","volume":"34","author":"Liu","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bmc.2026.118733_bb0120","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.thromres.2021.11.004","article-title":"The impact of warfarin on overall survival in cancer patients","volume":"213","author":"Chiasakul","year":"2022","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.bmc.2026.118733_bb0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0781.2000.160306.x","article-title":"The effect of PUVA on Langerhans cells in rat oral epithelium photosensitized with systemic methoxsalen or topical trioxsalen","volume":"16","author":"Kuusilehto","year":"2000","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"22","key":"10.1016\/j.bmc.2026.118733_bb0130","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1002\/cam4.4768","article-title":"A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond","volume":"11","author":"Noel","year":"2022","journal-title":"Cancer Med."},{"issue":"48","key":"10.1016\/j.bmc.2026.118733_bb0135","doi-asserted-by":"crossref","first-page":"15529","DOI":"10.1021\/ja065793p","article-title":"Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90","volume":"128","author":"Burlison","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0140","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI112983","article-title":"Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model","volume":"79","author":"Eder","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bmc.2026.118733_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155876","article-title":"Daphnetin induces ferroptosis in ovarian cancer by inhibiting NAD(P)H:Quinone oxidoreductase 1 (NQO1)","volume":"132","author":"Ma","year":"2024","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0150","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s43440-021-00261-z","article-title":"Mechanistic interplay of various mediators involved in mediating the neuroprotective effect of daphnetin","volume":"73","author":"Singh","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.bmc.2026.118733_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/0109298673298471240605072658","article-title":"Determination of inhibitory effect of PKM2 enzyme and Antitumoral activity of novel Coumarin-naphthoquinone hybrids","volume":"32","author":"de Andrade","year":"2025","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0160","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.bmc.2026.118733_bb0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","article-title":"Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer","volume":"14","author":"Liao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10637-009-9335-4","article-title":"A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells","volume":"29","author":"Singh","year":"2011","journal-title":"Investig. New Drugs"},{"issue":"50","key":"10.1016\/j.bmc.2026.118733_bb0175","doi-asserted-by":"crossref","first-page":"61899","DOI":"10.1021\/acsomega.5c08635","article-title":"Coumarin-1,2,3-Triazole conjugates as molecular scaffolds for the selective induction of ROS-driven apoptosis in Cancer cells in the development of pyruvate kinase M2 inhibitors","volume":"10","author":"Ouverney","year":"2025","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137751","article-title":"Modulation of tumour pyruvate kinase M2 and suppression of cancer cell proliferation using natural and synthetic antioxidants","volume":"1305","author":"Kapoor","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.bmc.2026.118733_bb0190","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/jm901577g","article-title":"Evaluation of substituted N,N\u2032-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"53","author":"Boxer","year":"2010","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bmc.2026.118733_bb0195","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1039\/D4MD00367E","article-title":"Novel sulfonamides unveiled as potent anti-lung cancer agents via tumor pyruvate kinase M2 activation","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104653","article-title":"Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators","volume":"108","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bmc.2026.118733_bb0205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2012.07.021","article-title":"Small molecule activation of PKM2 in Cancer cells induces serine Auxotrophy","volume":"19","author":"Kung","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bmc.2026.118733_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112844","article-title":"Paradigm shift of \u201cclassical\u201d HDAC inhibitors to \u201chybrid\u201d HDAC inhibitors in therapeutic interventions","volume":"209","author":"Vaidya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0215","series-title":"LH. Dimeric immuno-modulatory compounds against cereblon-based mechanisms","author":"Burnette","year":"2020"},{"issue":"2","key":"10.1016\/j.bmc.2026.118733_bb0220","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cber.19100430257","article-title":"Darstellung organischer Jodide aus den entsprechenden Bromiden und Chloriden","volume":"43","author":"Finkelstein","year":"1910","journal-title":"Ber. Dtsch. Chem. Ges."},{"issue":"17","key":"10.1016\/j.bmc.2026.118733_bb0225","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O\u2019Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"5","key":"10.1016\/j.bmc.2026.118733_bb0230","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/acs.jmedchem.3c01512","article-title":"Mechanistic investigation of thiazole-based pyruvate kinase M2 inhibitor causing tumor regression in triple-negative breast cancer","volume":"67","author":"Das","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106112","article-title":"Novel imidazopyrimidines-based molecules induce tetramerization of tumor pyruvate kinase M2 and exhibit potent antiproliferative profile","volume":"170","author":"Patel","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bmc.2026.118733_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108029","article-title":"Development of novel tetrazole-based pyruvate kinase M2 inhibitors targeting U87MG glioblastoma cells","volume":"154","author":"Chowdhury","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"33","key":"10.1016\/j.bmc.2026.118733_bb0245","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1021\/acs.biochem.6b00658","article-title":"Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5\u2032-phosphate (SAICAR) activates pyruvate kinase isoform M2 (PKM2) in its dimeric form","volume":"55","author":"Yan","year":"2016","journal-title":"Biochemistry"},{"issue":"7424","key":"10.1016\/j.bmc.2026.118733_bb0250","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nature11540","article-title":"Serine is a natural ligand and allosteric activator of pyruvate kinase M2","volume":"491","author":"Chaneton","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bmc.2026.118733_bb0255","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1021\/acs.biochem.7b01270","article-title":"Native mass spectrometry gives insight into the allosteric binding mechanism of M2 pyruvate kinase to Fructose-1,6-bisphosphate","volume":"57","author":"Gavriilidou","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2026.118733_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118416","article-title":"Phthalimide\u2013benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization","volume":"131","author":"Hoti","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108689","article-title":"Fluorenyl-phthalimide hybrids as potent aldose reductase inhibitors with selective anticancer activity: rational design, synthesis, and molecular insights","volume":"163","author":"Gundogdu","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"15","key":"10.1016\/j.bmc.2026.118733_bb0270","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1016\/j.bmc.2015.05.041","article-title":"New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2026.118733_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.144795","article-title":"Exploring Ugi-driven tetrazole chemistry for the discovery of pyruvate kinase M2 activators in glioblastoma management","volume":"1353","author":"Chowdhury","year":"2026","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bmc.2026.118733_bb0280","article-title":"Modified Annexin V\/Propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0285","article-title":"Assaying cell cycle status using flow cytometry","volume":"111","author":"Kim","year":"2015","journal-title":"Curr Protoc Mol Biol"},{"key":"10.1016\/j.bmc.2026.118733_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819841066","article-title":"Multiplexed single-cell measurements of FDG uptake and lactate release using droplet microfluidics","volume":"18","author":"Sengupta","year":"2019","journal-title":"Technol Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.bmc.2026.118733_bb0295","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1172\/JCI120912","article-title":"Endothelial pyruvate kinase M2 maintains vascular integrity","volume":"128","author":"Kim","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bmc.2026.118733_bb0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3892\/ijo.2014.2732","article-title":"Real-time quantitative RT-PCR detection of circulating tumor cells from breast cancer patients","volume":"46","author":"Guo","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"W1","key":"10.1016\/j.bmc.2026.118733_bb0305","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:22:02Z","timestamp":1786015322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":61,"alternative-id":["S0968089626001896"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118733","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coumarin\u2013sulfonamide hybrids as PKM2 activators induce metabolic reprogramming and suppress ovarian cancer cell growth","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118733"}}